These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14522477)

  • 21. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction.
    Gibson CM; Anshelevich M; Murphy S; Luu L; Hynes C; Kliris J; Kermgard S; Otten MH; Antman EM; Cannon CP; Braunwald E;
    Am J Cardiol; 2000 Dec; 86(12):1378-9, A5. PubMed ID: 11113418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Too much, too little, or none at all: dealing with substandard and fake drugs.
    Wan Po AL
    Lancet; 2001 Jun; 357(9272):1904. PubMed ID: 11425409
    [No Abstract]   [Full Text] [Related]  

  • 24. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from randomized clinical trials.
    Dong L; Zhang F; Shu X
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):135-44. PubMed ID: 20435991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in antithrombotic therapy of acute myocardial infarction.
    Gensini GF; Comeglio M; Falai M
    Am Heart J; 1999 Aug; 138(2 Pt 2):S171-6. PubMed ID: 10426878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
    Kereiakes DJ; Grines C; Fry E; Esente P; Hoppensteadt D; Midei M; Barr L; Matthai W; Todd M; Broderick T; Rubinstein R; Fareed J; Santoian E; Neiderman A; Brodie B; Zidar J; Ferguson JJ; Cohen M;
    J Invasive Cardiol; 2001 Apr; 13(4):272-8. PubMed ID: 11287711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coupling drug and catheter therapy for myocardial infarction.
    Lincoff AM
    JAMA; 2004 Feb; 291(8):1000-2. PubMed ID: 14982917
    [No Abstract]   [Full Text] [Related]  

  • 30. Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial.
    Kanakakis J; Nanas JN; Tsagalou EP; Maroulidis GD; Drakos SG; Ntalianis AS; Tzoumele P; Skoumbourdis E; Charbis P; Rokas S; Anastasiou-Nana M
    Catheter Cardiovasc Interv; 2009 Sep; 74(3):398-405. PubMed ID: 19360864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissolution of thrombus formed during direct coronary angioplasty with a single 10 mg intracoronary bolus dose of abciximab.
    Thuraisingham S; Tan KH
    Int J Clin Pract; 1999 Dec; 53(8):604-7. PubMed ID: 10692754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery of coronary flow and left ventricular function after abciximab.
    Mak KH; Neumann FJ; Blasini MR; Schmitt MC; Alt ME; Dirschinger MJ; Gawaz MM; Kastrati MA; Schömig MA
    Circulation; 1999 Nov; 100(22):e110. PubMed ID: 10578011
    [No Abstract]   [Full Text] [Related]  

  • 34. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.
    Welsh RC; Gordon P; Westerhout CM; Buller CE; O'Neill B; Armstrong PW
    Catheter Cardiovasc Interv; 2007 Sep; 70(3):341-8. PubMed ID: 17295333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.
    Califf RM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S33-7. PubMed ID: 10650314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
    Tcheng JE; Campbell ME
    J Am Coll Cardiol; 2003 Oct; 42(7):1196-8. PubMed ID: 14522479
    [No Abstract]   [Full Text] [Related]  

  • 38. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
    van den Merkhof LF; Zijlstra F; Olsson H; Grip L; Veen G; Bär FW; van den Brand MJ; Simoons ML; Verheugt FW
    J Am Coll Cardiol; 1999 May; 33(6):1528-32. PubMed ID: 10334418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship.
    Kandzari DE; Tcheng JE; Harrington RA; Sketch MH
    J Invasive Cardiol; 2000 Oct; 12(10):502-4. PubMed ID: 11022208
    [No Abstract]   [Full Text] [Related]  

  • 40. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.